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Life expectancy of individuals on combination antiretroviral 
therapy in high-income countries: a collaborative analysis of 
14 cohort studies
The Antiretroviral Therapy Cohort Collaboration*
Summary 
Background Combination antiretroviral therapy has led to signiﬁ cant increases in survival and quality of life, but at a 
population-level the eﬀ ect on life expectancy is not well understood. Our objective was to compare changes in mortality 
and life expectancy among HIV-positive individuals on combination antiretroviral therapy.
Methods The Antiretroviral Therapy Cohort Collaboration is a multinational collaboration of HIV cohort studies in 
Europe and North America. Patients were included in this analysis if they were aged 16 years or over and 
antiretroviral-naive when initiating combination therapy. We constructed abridged life tables to estimate life 
expectancies for individuals on combination antiretroviral therapy in 1996–99, 2000–02, and 2003–05, and stratiﬁ ed 
by sex, baseline CD4 cell count, and history of injecting drug use. The average number of years remaining to be lived 
by those treated with combination antiretroviral therapy at 20 and 35 years of age was estimated. Potential years of life 
lost from 20 to 64 years of age and crude mortality rates were also calculated.
Findings 18 587, 13 914, and 10 854 eligible patients initiated combination antiretroviral therapy in 1996–99, 2000–02, 
and 2003–05, respectively. 2056 (4·7%) deaths were observed during the study period, with crude mortality rates 
decreasing from 16·3 deaths per 1000 person-years in 1996–99 to 10·0 deaths per 1000 person-years in 2003–05. 
Potential years of life lost per 1000 person-years also decreased over the same time, from 366 to 189 years. Life 
expectancy at age 20 years increased from 36·1 (SE 0·6) years to 49·4 (0·5) years. Women had higher life expectancies 
than did men. Patients with presumed transmission via injecting drug use had lower life expectancies than did those 
from other transmission groups (32·6 [1·1] years vs 44·7 [0·3] years in 2003–05). Life expectancy was lower in patients 
with lower baseline CD4 cell counts than in those with higher baseline counts (32·4 [1·1] years for CD4 cell counts 
below 100 cells per μL vs 50·4 [0·4] years for counts of 200 cells per μL or more).
Interpretation Life expectancy in HIV-infected patients treated with combination antiretroviral therapy increased 
between 1996 and 2005, although there is considerable variability between subgroups of patients. The average number of 
years remaining to be lived at age 20 years was about two-thirds of that in the general population in these countries.
Funding UK Medical Research Council, GlaxoSmithKline.
Introduction
Treatment with antiretroviral drugs of people infected 
with HIV-1 has improved signiﬁ cantly since the 
introduction of combination antiretroviral therapy 
in 1996. In treatment-naive patients, ﬁ rst-line combination 
therapy selection is generally derived from two diﬀ erent 
forms of regimen, which contains either non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) or protease 
inhibitors (PIs).1 Both regimens function by suppressing 
viral replication and rapidly increasing CD4 cell counts.2
Over the past decade, combination therapy regimens 
have become more eﬀ ective, better tolerated, and have 
been simpliﬁ ed in terms of dosing.3–8 Clinical trials and 
observational studies have shown profound reductions 
in mortality and morbidity in patients infected with HIV 
as a result of combination antiretroviral therapy.9–18 This 
decrease in mortality is particularly apparent in 
industrialised, high-income countries where access to 
health care and antiretroviral treatments is more readily 
available.19
Life expectancy and mortality are universally viewed as 
important population health indicators. As such, several 
studies have displayed the negative relation between HIV 
prevalence and life expectancy at a population level.20 
However, the eﬀ ect of HIV on life expectancy in the era 
of combination therapy is not well understood because of 
the relative novelty of this treatment. The objective of this 
study was to compare changes in mortality rates and life 
expectancy among HIV-positive individuals on com-
bination therapy in high-income countries over three 
separate periods (1996–99, 2000–02, and 2003–05) and in 
subgroups deﬁ ned by patient characteristics at initiation 
of such treatment. 
Methods
Participants
The Antiretroviral Therapy Cohort Collaboration 
(ART-CC) is a multinational cohort study of anti retro-
viral-naive HIV-positive patients initiating com bina tion 
anti retroviral therapy.21–23 The collaboration was estab-
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lished in 2001, with datasets updated in 2004 and 2007, 
and includes cohort studies in Canada, Europe, and the 
USA.
Cohort studies were eligible to join if they had enrolled 
at least 100 HIV-1-infected antiretroviral-naive patients 
aged 16 years or older who initiated potent combination 
therapy with at least three antiretrovirals and had been 
followed up for median duration of at least 1 year. All 
prospective studies that joined the collaboration have 
been approved by their local ethics committees or 
institutional review boards, use standardised methods of 
data collection, and schedule follow-up visits at least once 
every 6 months.
Data collection
Patient selection and data extraction were done at the 
data centres of the participating cohort studies. 
Non-nominal data from each cohort on a predeﬁ ned set 
of demographic, laboratory, and clinical variables were 
then pooled and analysed centrally. Cohort data 
managers from EuroSIDA were asked to provide a 
unique study identiﬁ cation for each record, since 
EuroSIDA patients could also be members of other 
cohort studies and therefore could potentially be 
included in the dataset twice. 14 cohorts were included 
in the analysis: the 1917 Clinic Cohort (USA; n=646), 
Aquitaine Cohort (France; 950), AIDS Therapy 
Evaluation project Netherlands (ATHENA; Nether-
lands; 5661), British Columbia Centre for Excellence in 
HIV/AIDS (BCCfE-HIV; Canada; 1363), Köln/Bonn 
Cohort (Germany, 627), Collaborations in HIV Outcomes 
Research US (CHORUS; USA; 1596), the Multi center 
Study Group on EuroSIDA (Europe and Argentina; 
1658), French Hospital Database on HIV (FHDH; 
France; 19 095), Frankfurt HIV Cohort (Germany; 1965), 
Italian Cohort of Antiretroviral-Naive Patients (ICONA; 
Italy; 3003), Proyecto para la Informatización del 
Seguimiento Clínico-epidemiológico de la Infección por 
HIV y SIDA (PISCIS; Spain; 2511), Royal Free Hospital 
Cohort (UK; 867), South Alberta Clinic (Canada; 407), 
and the Swiss HIV Cohort Study (SHCS; Switzer-
land; 3006). Some cohorts participating in the 
collaboration were excluded from this study because 
their data were not available at the time of these 
analyses.
Information on all cause mortality was obtained either 
through linkages with Vital Statistics agencies or 
through active follow-up of cohort participants. Patients 
1996–99 (N=18 587) 2000–02 (N=13 914) 2003–05 (N=10 854)
Age (years)
Median 36 (31–43) 37 (31–44) 38 (32–45)
16–29 years 3106 (16·7%) 2481 (17·8%) 1935 (17·8%)
30–39 years 9039 (48·6%) 5916 (42·5%) 4181 (38·5%)
40–49 years 4248 (22·9%) 3614 (26·0%) 3123 (28·8%)
50+ years 2194 (11·8%) 1903 (13·7%) 1615 (14·9%)
Sex
Female 4045 (21·8%) 4133 (29·7%) 3572 (32·9%)
Male 14 542 (78·2%) 9781 (70·3%) 7282 (67·1%)
Risk factor for transmission
Injecting drug use 3495 (18·8%) 1836 (13·2%) 910 (8·4%)
Other 15 092 (81·2%) 12 078 (86·8%) 9944 (91·6%)
CD4 cell count (cells per μL)
<100 4848 (26·1%) 4104 (29·5%) 2769 (25·5%)
100–199 3165 (17·0%) 2943 (21·2%) 2395 (22·1%)
≥200 10 574 (56·9%) 6867 (49·3%) 5690 (52·4%)
Clinical CDC stage
A/B 14 258 (76·7%) 10 467 (75·2%) 8576 (79·0%)
C 4329 (23·3%) 3447 (24·8%) 2278 (21·0%)
Plasma HIV RNA level (log10 copies per mL)
<4·00 2533 (13·6%) 1798 (12·9%) 1439 (13·3%)
4·00–4·99 7543 (40·6%) 5403 (38·8%) 4260 (39·3%)
≥5·00 8511 (45·8%) 6713 (48·3%) 5155 (47·5%)
Initial drug regimen
PI-based 14 530 (78·2%) 5977 (43·0%) 5375 (49·5%)
NNRTI-based 3072 (16·5%) 5547 (39·9%) 4248 (39·1%)
Three NRTIs 620 (3·3%) 1994 (14·3%) 969 (8·9%)
Other 365 (2·0%) 396 (2·8%) 262 (2·4%)
Data are median (IQR) or n (%). NNRTI=non-nucleoside reverse transcriptase inhibitor. NRTI=nucleoside reverse 
transcriptase inhibitor. PI=protease inhibitor.
Table 1: Baseline characteristics of patients initiating combination antiretroviral therapy by period 
of initiation
1996–99 2000–02 2003–05 1996–2005
Mortality rates (per 1000 person-years)
Overall 16·3 (14·9–17·8) 12·4 (11·5–13·2) 10·0 (9·3–10·8) 12·0 (11·5–12·5)
Between the ages 20 and 44 years 13·1 (11·7–14·7) 10·3 (9·4–11·2) 7·5 (6·8–8·3) 9·7 (9·1–10·2)
Potential years of life lost before age 65 years (per 1000 person-years)
20–64 years 365·9 260·4 189·4 247·0
Life expectancy (years; adjusted)
At exact age 20 years 36·1 (SE 0·60) 41·2 (SE 0·52) 49·4 (SE 0·54) 43·1 (SE 0·33)
At exact age 35 years 25·0 (SE 0·42) 30·1 (SE 0·31) 37·3 (SE 0·37) 31·7 (SE 0·21)
Percent surviving from 20 to 44 years 75·5% 79·5% 85·7% 81·1%
Mortality rates are deaths per 1000 person-years (95% CI).
Table 2: Health indicators for overall (20 years or older) population by period of follow-up
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were included in this analysis if they were aged 16 years 
or older, were antiretroviral naive when initiating 
combination therapy, and did not receive fusion 
inhibitors in their initial regimen. Patients’ analysis 
time started on the date they started combination 
therapy (after Jan 1, 1996); follow-up was censored at 
Dec 31, 2005.
Statistical analysis
Crude (all ages) and age-speciﬁ c mortality rates for 
individuals with age between 20 and 44 years were 
calculated. Mortality rates (per 1000 person-years) were 
calculated by dividing the total number of deaths by the 
total number of person-years of follow-up. Mortality 
rates were stratiﬁ ed by sex, transmission group (injecting 
drug use vs other), and baseline CD4 cell count (<100, 
100–199, ≥200 cells per μL). Rates in periods deﬁ ned by 
period of initiation of combination therapy and period of 
follow-up were internally standardised by including 
centred values of prognostic variables (values with mean 
zero) in Poisson regression models.
Potential years of life lost (PYLL) were calculated as the 
sum of years that HIV-positive participants in our 
analyses lost because of premature death.24,25 PYLL is 
calculated with death before the age of 65 years being 
considered premature, since this is deemed to be the age 
at which most people retire. PYLL were expressed as per 
1000 person-years from age 20 to 64 years. Values were 
stratiﬁ ed by sex, transmission group, and baseline CD4 
cell count.
Abridged life tables were constructed from age-speciﬁ c 
mortality rates to compare life expectancies at the age of 
20 years in 1996–99, 2000–02, and 2003–05. Large 
populations are needed to overcome systematic and 
random variations in mortality when building complete 
life tables, therefore abridged life tables were used in 
this study. These tables describe the mortality experience 
that hypothetical cohorts of HIV-positive individuals 
would have had if they were subjected to the mortality 
rates in the observed calendar periods. The life 
expectancy at an exact age is a demographic indicator 
that measures the average number of additional years 
that will be lived by a person after that age, according to 
the cross-sectional age-speciﬁ c mortality rates for all 
causes of death during the study period. Life expectancy 
values at exact ages 20 and 35 years were reported for 
the total cohort as well as stratiﬁ ed by sex, transmission 
group, and baseline CD4 cell count. Detailed information 
on the calculations of life tables, potential years of life 
lost, crude and age-speciﬁ c mortality rates can be found 
in webappendices 2 and 3.
Analyses were done with Stata version 10.0 and 
Microsoft Excel 2008.
Role of the funding source
The study sponsors had no role in the design or con duct 
of this study, or in the collection, analysis, or interpretation 
of the data. The corresponding author, Margaret May, 
and Jonathan Sterne had full access to all the data. The 
corresponding author had the ﬁ nal responsibility for the 
decision to submit for pub lication.
Results
Our analyses were based on 43 355 eligible patients and 
2050 (4·7%) deaths from the 14 participating cohorts. 
Table 1 shows the distribution of baseline variables of 
interest according to calendar period of initiation of 
combination antiretroviral therapy. Because of the large 
sample size, there were statistically signiﬁ cant diﬀ erences 
in the distribution of all variables over the three periods 
studied, although the magnitudes of some diﬀ erences 
were small. Over time, there were increases in median 
age, and in the proportion of participants who were 
women, who did not have a history of injecting drug use, 
who had CDC clinical stage A/B disease (ie, no 
pre-antiretroviral therapy AIDS-deﬁ ning event), and were 
on non-PI-based regimens.
Table 2 shows mortality rates, PYLLs, and life 
expectancy at ages 20 and 35 years for the entire cohort. 
Overall mortality rates (20 years and above), mortality 
rates  between the ages of 20 and 44 years, and PYLLs 
declined between 1996–99 and 2003–05. Between 
1996–99 and 2003–05, there was a gain in life expectancy 
for those at age 20 years of about 13 years; similar gains 
in life expectancy in those aged 35 years were also seen. 
Table 3 reports crude and internally standardised 
mortality rates by period of initiation and period of 
follow-up of combination therapy. There were declines 
in mortality rates by both period of initiation and period 
of follow-up.
Table 4 shows the same health indicators as in table 2 
stratiﬁ ed by sex and transmission group (ie, injecting 
drug use vs non-injecting drug use). Women had lower 
mortality rates and PYLLs and somewhat higher life 
expectancies than did men. Individuals with a history of 
injecting drug use also had higher rates of mortality and 
lower life expectancy than did non-injecting drug users. 
Life expectancy at age 20 years and at age 35 years was 
1996–99 2000–02 2003–05
Crude mortality rates
Initiated 1996–99 16·3 (14·9–17·8)* 11·4 (10·4–12·4) 9·9 (8·9–11·0)
Initiated 2000–02 ·· 14·7 (13·2–16·5)* 8·7 (7·7–9·8)
Initiated 2003–05 ·· ·· 13·3 (11·5–15·4)*
Standardised mortality rates†
Initiated 1996–99 12·9 (11·8–14·2)* 9·2 (8·4–10·0) 8·1 (7·2–9·1)
Initiated 2000–02 ·· 11·1 (9·9–12·5)* 6·7 (5·9–7·6)
Initiated 2003–05 ·· ·· 10·3 (8·9–12·0)*
Data are deaths per 1000 person-years (95% CI). *Follow-up restricted to the same period during which combination 
therapy was initiated. †Standardised rates were internally standardised by sex, age at initiation of combination 
therapy, presumed mode of transmission (injecting drug use vs other), and CD4 cell count.
Table 3: Crude and standardised rates of mortality by period of initiation and period of follow-up
See Online for webappendices 2 
and 3
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lower in injecting drug users than in non-injecting drug 
users.
Table 5 displays mortality rates, PYLLs, and life 
expectancy stratiﬁ ed by baseline CD4 cell count. Overall 
mortality rates, mortality rates between the ages of 20 and 
44 years, and PYLLs decreased substantially with in-
creasing CD4 cell count at baseline, as did life expectancy 
at age 20 years and at age 35 years.
Sensitivity analyses were done to examine the eﬀ ect of 
cohorts from France on our estimates of life expectancy 
in the main analyses, since the two French cohorts 
(n=20 695) represent nearly half our study population 
and the majority of people who initiated combination 
therapy in France since 1996. The overall mortality rates 
in the French cohorts were very similar to those reported 
in cohorts from other countries (webtable). Life 
expectancy at 20 years was 43·6 years in the French 
cohorts and 43·0 years in non-French cohorts, and 
32·5 years in French cohorts and 31·5 years in non-French 
cohorts at 35 years.
Discussion
Our analysis of 14 cohort studies and 43 355 HIV-infected 
patients indicate that there has been an improvement of 
outcomes with combination anti retroviral therapy 
between 1996 and 2005, characterised by a marked 
decrease in mortality rates and potential years of life lost, 
and by corresponding increases in life expectancy and 
the proportion of patients surviving from age 20 to age 
44 years. Life expectancy diﬀ ers markedly between 
subgroups deﬁ ned by patient characteristics at initiation 
of combination therapy, and is notably lower in patients 
with presumed transmission via injecting drug use and 
who initiated treatment at lower CD4 cell counts.
Previous studies have shown similar decreases in 
mortality rates and increases in life expectancy as a result 
of combination therapy.26–33 However, such ﬁ ndings have 
been restricted to countrywide analyses, and have often 
been localised at the provincial or state level.30,31 
Additionally, all previous studies have been based on 
substantially smaller samples. One of the larger studies, 
which took place in the USA, analysed a cohort of nearly 
5000 HIV-infected patients and exhibited similar survival 
beneﬁ ts for individuals being treated with combination 
antiretroviral therapy.29 However, the study did not take 
into account previous exposure to antiretroviral therapy 
before initiation of combination treatment, which may 
be a confounding factor. By contrast, all patients in our 
analysis were treatment naive at initiation of combination 
therapy. 
The progressive reductions in mortality and gains in 
life expectancy over the three periods studied here are 
probably the result of both improvements in therapy 
during the ﬁ rst decade of combination therapy and 
continuing declines in mortality rates among individuals 
on such treatment for long periods. These results lend 
further credence to earlier reports. In a recent study by 
Lima and colleagues,31 2238 HIV-infected antiretroviral-
naive patients initiating therapy in British Columbia, 
Canada,  were surveyed over several periods between 1993 
and 2004. The authors noted the vast improvements in 
drug regimens since the pre-combination antiretroviral 
therapy era as well as over the course of development of 
combination treatment. In the early era of antiretroviral 
therapy, monotherapies were the main form of treatment. 
Since the advent of combination antiretroviral therapy, 
triple antiretroviral combinations have become the 
standard of care for HIV-infected patients in high-income 
countries and have improved substantially as treatments 
Men Women Injecting drug users Non-injecting drug users
Mortality rates (per 1000 person-years)
Overall 12·9 (12·3–13·6) 9·1 (8·2 – 10·1) 20·7 (19·0–22·5) 10·5 (10·0–11·0)
Between the ages 20 and 44 years 10·3 (9·7 –11·0) 7·9 (7 – 8·9) 18·6 (16·9–20·6) 7·8 (7·2–8·3)
Potential years of life lost before age 65 years (per 1000 person-years)
20–64 years 257·8 214·4 505·5 202·5
Life expectancy (years; adjusted)
Exact age 20 years 42·8 (SE 0·45) 44·2 (SE 0·55) 32·6 (SE 1·06) 44·7 (SE 0·34)
Exact age 35 years 31·7 (SE 0·24) 32·5 (SE 0·44) 23·4 (SE 0·60) 33·0 (SE 0·22)
Percent surviving from 20 to 44 years 80·2% 83·1% 66·5% 84·1%
Mortality rates are deaths per 1000 person-years (95% CI).
Table 4: Health indicators stratiﬁ ed by sex and injecting drug use
<100 cells per μL 100–199 cells per μL ≥200 cells per μL
Mortality rates (per 1000 person-years)
Overall 21·4 (20·1–22·8) 13·4 (12·2–14·8) 7·0 (6·4–7·5)
Between the ages 20 and 44 years 19·7 (18·1–21·3) 10·7 (9·4–12·2) 5·0 (4·5–5·6)
Potential years of life lost before age 65 years (per 1000 person-years)
20–64 years 460·9 264·9 138·3
Life expectancy (years; adjusted)
Exact age 20 years 32·4 (SE 1·09) 42·0 (SE 0·62) 50·4 (SE 0·41)
Exact age 35 years 27·0 (SE 0·37) 30·4 (SE 0·45) 37·2 (SE 0·33)
Percent surviving from 20 to 44 years 59·8% 80·6% 89·9%
Mortality rates are deaths per 1000 person-years (95% CI).
Table 5: Health indicators stratiﬁ ed by baseline CD4 cell count
See Online for webtable
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developed. These advances in treatment have transformed 
HIV from being a fatal disease, which was the reality for 
patients before the advent of combination treatment, 
into a long-term chronic con dition. In fact, a number of 
studies have found that AIDS-deﬁ ning illnesses as the 
cause of death are declining dramatically:27,34,35 Because of 
improvements in treatment, fewer HIV-infected patients 
are dying of characteristic HIV-related illnesses, such as 
non-Hodgkin lymphoma.36
Despite these reassuring results, there is still a large 
discrepancy between the life expectancy of the general 
population and the life expectancy of an HIV-infected 
individual. A person starting combination therapy can 
expect to live about 43 years at 20 years of age, about 
two-thirds as long as the general population in these 
countries. This discrepancy in life expectancy could be 
attributed to active HIV infection or to other underlying 
lifestyle, socioeconomic, and health issues. Further 
research must be devoted to the ongoing improvement 
of antiretroviral therapy to lessen the gap between the life 
expectancy of HIV-infected patients and the general 
population, as well as to improve the quality of life of 
individuals living with HIV.
There is also considerable heterogeneity between 
subgroups in life expectancy. For example, the disparity 
in life expectancy between HIV-infected injecting drug 
users and non-injecting drug users is very large. This 
ﬁ nding is consistent with previous ﬁ ndings.32,37 There 
may be several reasons for this discrepancy, such as 
issues of adherence, inadequate or unequal access to 
treatment, active illicit drug use, hepatitis C co-infection, 
higher rates of smoking and alcohol use, and 
socioeconomic status.38 The increasing proportion of 
women starting combination therapy could be the result 
of migration of women infected through heterosexual 
sex in sub-Saharan Africa: a number of settings have 
reported higher numbers of sub-Saharan African women 
accessing therapy in the past few years.39 Higher life 
expectancy in women could be due to the higher median 
baseline CD4 cell count in women, because women tend 
to be diagnosed earlier in the course of their infection, in 
antenatal settings.
Our life expectancy results are representative of all 
individuals who started combination therapy, including 
those who did not remain on such treatment 
throughout follow-up. Therefore, the changes in 
mortality and life expectancy over time might reﬂ ect 
not only the long-term tolerability and diminishing 
side-eﬀ ects of antiretroviral drugs, but also reductions 
in rates of treatment discontinuation and non-
adherence. A previous article40 found little evidence 
that short-term (1 year) survival had improved 
between 1996 and 2003, despite an improvement in 
virological response after initiation of combination 
therapy. The reductions in mortality rates and 
corresponding improvements in life expectancy seen 
here probably reﬂ ect both improvements in 3 year 
survival apparent in the extended and updated dataset 
analysed here, and the continuing declines in mortality 
rates among patients on combination therapy for 
extended periods.
Our study is potentially limited by the under-reporting 
of deaths by some cohorts that do not actively link to 
administrative records. Such under-reporting could 
imply that the mortality rates reported here are 
underestimates. The reporting methods among the 
cohorts participating in this study were not the same; 
some cohorts used record linkages done with vital 
statistics, while others used self-reporting systems to 
monitor mortality rates. We were reassured by the lack 
of diﬀ erence in mortality rates between the French and 
non-French cohorts. Furthermore, we were not able to 
distinguish between active and a history of injecting 
drug use or the eﬀ ect of subsequent changes in 
antiretroviral therapy over the period of observation. We 
do not have detailed data on causes of death, although 
we are currently collecting available information for all 
patients and, where possible, using this to categorise 
causes of death. Preliminary data suggest that 85% of 
patients who died had some information on cause of 
death. Of these, about 50% died of an AIDS-deﬁ ning 
condition. Other major causes of death included 
non-AIDS malignancy, heart disease, infection, violent 
causes (including suicide and substance abuse), and 
liver-related causes. Lastly, the estimation of mortality in 
the last open interval (65 years and more) is diﬃ  cult 
because the person-years of follow-up in this interval is 
limited—few patients in our study are over the age of 
65 years and those patients who are enrolled tend to be 
younger (within this age-group) than those in the general 
population. Therefore, mortality rates were adjusted in 
this open interval to limit the eﬀ ect of the under 
ascertainment of deaths (webappendix 2). Our results 
are similar to those reported from Denmark for people 
on treatment since the mid-1990s.41 However, extended 
follow-up of older HIV-infected patients treated with 
combination antiretroviral therapy will be needed to 
produce reliable estimates of mortality rates in these 
groups, and improved estimates of life expectancy for all 
patients.
In summary, the results of this study indicate that 
people living with HIV in high-income countries can 
expect increasing positive health outcomes on 
combination antiretroviral therapy. The marked increase 
in life expectancy since 1996 is a testament to the gradual 
improvement and overall success of such treatment. 
Because there is still a large discrepancy in life 
expectancy between the general population and 
HIV-infected individuals, we encourage health planners 
to use these data to improve health services and living 
conditions for such people. Cohort studies must 
continue to observe and monitor individuals initiating 
combination antiretroviral therapy to monitor long-term 
eﬀ ects and toxicities.
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